Josh DeClercq

604 total citations
42 papers, 346 citations indexed

About

Josh DeClercq is a scholar working on Family Practice, Pediatrics, Perinatology and Child Health and Economics and Econometrics. According to data from OpenAlex, Josh DeClercq has authored 42 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Family Practice, 10 papers in Pediatrics, Perinatology and Child Health and 10 papers in Economics and Econometrics. Recurrent topics in Josh DeClercq's work include Medication Adherence and Compliance (14 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Pharmaceutical Practices and Patient Outcomes (9 papers). Josh DeClercq is often cited by papers focused on Medication Adherence and Compliance (14 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Pharmaceutical Practices and Patient Outcomes (9 papers). Josh DeClercq collaborates with scholars based in United States, Netherlands and Bermuda. Josh DeClercq's co-authors include Leena Choi, Autumn D. Zuckerman, Nisha Shah, David G. M. Mitchell, Nitin B. Jain, Anna R. Hemnes, Robert McCormick, John E. Kuhn, Keith M. Baumgarten and Gregory D. Ayers and has published in prestigious journals such as PLoS ONE, Journal of Bone and Joint Surgery and The American Journal of Gastroenterology.

In The Last Decade

Josh DeClercq

38 papers receiving 330 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Josh DeClercq United States 11 120 84 77 58 58 42 346
Michiko Inaba United States 11 21 0.2× 138 1.6× 68 0.9× 21 0.4× 19 0.3× 14 376
Ansgar Hebborn Switzerland 8 42 0.3× 20 0.2× 129 1.7× 66 1.1× 47 0.8× 12 481
Danielle Colayco United States 10 41 0.3× 73 0.9× 41 0.5× 95 1.6× 21 0.4× 18 403
Weilin Qi China 13 70 0.6× 43 0.5× 18 0.2× 127 2.2× 12 0.2× 30 450
Ibrahim E. Fahdi United States 7 155 1.3× 105 1.3× 55 0.7× 35 0.6× 11 0.2× 9 400
Shannon Cartier United States 8 68 0.6× 21 0.3× 12 0.2× 12 0.2× 48 0.8× 13 338
Lauren J. Lee United States 12 38 0.3× 7 0.1× 52 0.7× 57 1.0× 36 0.6× 27 550
Evan Davies United States 10 19 0.2× 8 0.1× 112 1.5× 62 1.1× 24 0.4× 31 366
Tami Wisniewski United States 11 39 0.3× 19 0.2× 15 0.2× 144 2.5× 48 0.8× 20 490

Countries citing papers authored by Josh DeClercq

Since Specialization
Citations

This map shows the geographic impact of Josh DeClercq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josh DeClercq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josh DeClercq more than expected).

Fields of papers citing papers by Josh DeClercq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josh DeClercq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josh DeClercq. The network helps show where Josh DeClercq may publish in the future.

Co-authorship network of co-authors of Josh DeClercq

This figure shows the co-authorship network connecting the top 25 collaborators of Josh DeClercq. A scholar is included among the top collaborators of Josh DeClercq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josh DeClercq. Josh DeClercq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barnes, J., et al.. (2024). Adherence and discontinuation of prescription cannabidiol for the management of seizure disorders at an integrated care center. Epilepsy Research. 200. 107300–107300. 4 indexed citations
2.
Renfro, Chelsea P., et al.. (2024). Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative. Journal of Managed Care & Specialty Pharmacy. 30(7). 710–718. 1 indexed citations
3.
DeClercq, Josh, et al.. (2024). Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis. Journal of Managed Care & Specialty Pharmacy. 30(4). 336–344. 1 indexed citations
4.
Zuckerman, Autumn D., et al.. (2023). Optimizing HIV PrEP Persistence: Does Your Pharmacy Matter?. AIDS and Behavior. 27(11). 3735–3744. 1 indexed citations
5.
Zuckerman, Autumn D., et al.. (2023). Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy. Journal of Managed Care & Specialty Pharmacy. 29(7). 732–739. 2 indexed citations
6.
7.
Zuckerman, Autumn D., Amy M. Smith, Jennifer L. Donovan, et al.. (2023). 2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services. American Journal of Health-System Pharmacy. 80(13). 827–841. 10 indexed citations
8.
Barnes, J., et al.. (2023). Therapy outcomes associated with prescription cannabidiol use at 12 months post-initiation. Epilepsy & Behavior. 147. 109412–109412.
9.
DeClercq, Josh, et al.. (2023). Does interaction occur between risk factors for revision total knee arthroplasty?. Archives of Orthopaedic and Trauma Surgery. 144(12). 5061–5070. 1 indexed citations
10.
Zuckerman, Autumn D., et al.. (2023). Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis. Multiple Sclerosis and Related Disorders. 75. 104738–104738. 1 indexed citations
11.
Hall, Nicole A., et al.. (2022). Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model. Journal of clinical lipidology. 16(3). 315–324. 8 indexed citations
12.
Cutler, Holt S., et al.. (2022). Risk of Revision Shoulder Arthroplasty After Anatomic and Reverse Total Shoulder Arthroplasty. Journal of the American Academy of Orthopaedic Surgeons. 31(1). 17–25. 13 indexed citations
13.
14.
Carver, Alicia, Josh DeClercq, Leena Choi, et al.. (2021). Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. The American Journal of Surgery. 223(5). 975–982. 14 indexed citations
15.
Zuckerman, Autumn D., et al.. (2021). Primary medication nonadherence calculation method specifications impact resulting rates. Research in Social and Administrative Pharmacy. 18(3). 2478–2483. 6 indexed citations
16.
DeClercq, Josh, Gregory D. Ayers, Laurence D. Higgins, et al.. (2020). Comparative Time to Improvement in Nonoperative and Operative Treatment of Rotator Cuff Tears. Journal of Bone and Joint Surgery. 102(13). 1142–1150. 24 indexed citations
17.
DeClercq, Josh, et al.. (2020). Pharmacist Interventions to Improve Specialty Medication Adherence: Study Protocol for a Randomized Controlled Trial. Drugs - Real World Outcomes. 7(4). 295–305. 6 indexed citations
18.
Zuckerman, Autumn D., et al.. (2019). Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?. PLoS ONE. 14(11). e0225434–e0225434. 6 indexed citations
19.
Shah, Nisha, et al.. (2019). High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. PLoS ONE. 14(6). e0217798–e0217798. 28 indexed citations
20.
Culver, Brady P., Josh DeClercq, Igor Dolgalev, et al.. (2016). Huntington’s Disease Protein Huntingtin Associates with its own mRNA. Journal of Huntington s Disease. 5(1). 39–51. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michiko Inaba Breakdown of academic impact, for papers by Ansgar Hebborn Breakdown of academic impact, for papers by Danielle Colayco Breakdown of academic impact, for papers by Weilin Qi Breakdown of academic impact, for papers by Ibrahim E. Fahdi Breakdown of academic impact, for papers by Shannon Cartier Breakdown of academic impact, for papers by Lauren J. Lee Breakdown of academic impact, for papers by Evan Davies Breakdown of academic impact, for papers by Tami Wisniewski
Rankless by CCL
2026